| [1] |
Witjes JA, Bruins HM, Carrión A，et al. 2022 EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer[EB/OL]. [2022-03-04].
URL
|
| [2] |
Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosur-veillance to tumor escape[J]. Nat Immunol, 2002, 3(11): 991-998.
|
| [3] |
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle[J]. Immunity, 2013, 39(1): 1-10.
|
| [4] |
黄健, 王建业, 孔垂泽, 等. 中国泌尿外科和男科疾病诊断治疗指南(2019版)[M]. 北京: 科学出版社, 2020.
|
| [5] |
Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial[J]. Nat Med, 2019, 25(11): 1706-1714.
|
| [6] |
Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as Neoad-juvant Therapy Before Radical Cystectomy in Patients With Mus-cle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study[J]. J Clin Oncol, 2018, 36(34): 3353-3360.
|
| [7] |
Necchi A, Raggi D, Gallina A, et al. Updated Results of PURE-01 with Prelimi-nary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies[J]. Eur Urol, 2020, 77(4): 439-446.
|
| [8] |
易小琦. PD-1/PD-L1抑制剂在膀胱癌新辅助治疗中的应用进展[J]. 实用肿瘤学杂志, 2022, 36: 183-187.
|
| [9] |
Wei XX, McGregor BA, Lee RJ, et al. Durvalumab as neo-adjuvant therapy for muscle invasive bladder cancer: preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2 [J]. J Clin Oncol, 2020, 38 suppl 6: 507.
|
| [10] |
Gao J, Navai N, Alhalabi O, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma[J]. Nat Med, 2020, 26(12): 1845-1851.
|
| [11] |
van Dijk N, Gil-Jimenez A, Silina K, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial[J]. Nat Med, 2020, 26(12): 1839-1844.
|
| [12] |
Dorp Jv. LBA31-High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer (NABUCCO cohort 2)[J]. Ann Oncol, 2021, 32 suppl 5: S1283-S1346.
|
| [13] |
Gupta S, Sonpavde G, Weight CJ, et al. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy[J]. J Clin Oncol, 2020, 38 suppl 6: 439.
|
| [14] |
Gupta S, Gibb E, Sonpavde GP, et al. Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscleinvasive bladder cancer (MIBC) undergoing cystectomy[J]. J Clin Oncol, 2022, 40 suppl 6: 528.
|
| [15] |
Martinez Chanza N, Soukane L, Barthelemy P, et al. Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder can-cer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004-AURA trial)[J]. BMC Cancer. 2021, 21(1): 1292.
|
| [16] |
Shen Y, Wen F, Zhang P, et al. Real-world study of chemotherapy plus immuno-therapy versus chemotherapy alone as neoadjuvant treatment guided bladder-sparing therapy for localized muscle-invasive bladder cancer[J]. J Clin Oncol, 2022, 40 suppl 6: 499.
|
| [17] |
Rosenberg JE, Powles T, Sonpavde GP, et al. Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemo-therapy in patients with previously treated advanced urothelial carcinoma[J]. J Clin Oncol, 2022, 40 suppl 16: 4516.
|
| [18] |
Zhou L, Xu HY, Li SM, et al. Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma[J]. J Clin Oncol 40, 2022, 40 suppl 6: 515.
|
| [19] |
Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus ob-servation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol. 2021, 22(4): 525-537.
|
| [20] |
Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma[J]. N Engl J Med. 2021, 384(22): 2102-2114.
|
| [21] |
Witjes A, Bajorin DF, Galsky MD. Results for patients with muscle-invasive bladder cancer (MIBC) in the CheckMate 274 trial[J]. J Clin Oncol 40, 2022, 40 suppl 16: 4585.
|
| [22] |
Galsky MD, Witjes JA, Gschwend JE, et al. Disease-free survvial with longer follow-up from the phase 3 CheckMate 274 trial of adjuvant nivolumab in patients who underwent surgery for high-risk muscle-invasive urothelial carcinoma. Poster presentation at the Society of Urologic Oncology (SUO) annual meeting, USA, 2021. Orlando: SUO, 2021.
|
| [23] |
Thomas WF, Philippe ES, Michael A, et al. NCCN Clinical Practice Guidelines in Oncology-Bladder cancer (Version2. 2022) [EB/OL]. [2022-05-20].
URL
|
| [24] |
Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer[J]. Eur Urol. 2012, 61(6): 1229-1238.
|
| [25] |
Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events As-sociated with Immune Checkpoint Blockade[J]. N Engl J Med. 2018, 378(2): 158-168.
|
| [26] |
Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunother-apy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, S0923-7534(22)04187-4, online ahead of print.
|
| [27] |
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with im-mune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group[J]. J Im-munother Cancer, 2017, 5(1): 95.
|
| [28] |
Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update[J]. J Clin Oncol, 2021, 39(36): 4073-4126
|
| [29] |
Thompson JA, Schneider BJ, Brahmer J, et al. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2022, 20(4): 387-405.
|